Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7051 to 7065 of 8905 results

  1. Transperineal biopsy for diagnosing prostate cancer (DG54)

    We have moved Diagnostics guidance 54 to become HealthTech guidance 680. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  2. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)

    We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    We have moved Diagnostics guidance 6 to become HealthTech guidance 292. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    We have moved Diagnostics guidance 11 to become HealthTech guidance 320. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  7. The EOS 2D/3D imaging system (DG1)

    We have moved Diagnostics guidance 1 to become HealthTech guidance 274. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)

    This guidance has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn guidance

  9. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    We have moved Diagnostics guidance 14 to become HealthTech guidance 353. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

    This guidance has been updated and replaced by NICE HealthTech guidance 552.

    Withdrawn guidance

  11. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    We have moved Diagnostics guidance 19 to become HealthTech guidance 388. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Cryotherapy for the treatment of liver metastases (IPG369)

    Interventional procedures, IPG369 - Issued: December 2010 --> We have moved interventional procedures guidance 369 to become HealthTech guidance 241. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome (IPG376)

    We have moved interventional procedures guidance 376 to become HealthTech guidance 248. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance